In one aspect, the invention relates to compounds having the formula:
where R
1
-R
6
, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
[EN] TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TÉTRAHYDRO-PYRIDO-PYRIMIDINE
申请人:NOVARTIS AG
公开号:WO2012004299A1
公开(公告)日:2012-01-12
The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT
申请人:Kataoka Tohru
公开号:US20140194412A1
公开(公告)日:2014-07-10
The present invention provides an anticancer drug having a Ras function inhibitory action.
The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I′):
wherein each symbol is as defined in the present specification, or a salt thereof.
[EN] Use of inhibitors of the activity or function of PI3K<br/>[FR] UTILISATION D'INHIBITEURS DE L'ACTIVITÉ OU DE LA FONCTION DE PI3K
申请人:NOVARTIS AG
公开号:WO2013088404A1
公开(公告)日:2013-06-20
The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
[EN] PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA<br/>[FR] INHIBITEURS PURIQUES DE LA PHOSPHATIDYLINOSITOL 3-KINASE DELTA HUMAINE
申请人:MERCK SHARP & DOHME
公开号:WO2014075392A1
公开(公告)日:2014-05-22
The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.